Qu Biologics
Qu Biologics is a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many conditions including cancer, inflammatory bowel disease, inflammatory lung disease and arthritis. SSIs are a broad platform technology being tested in multiple disease indications, including Health Canada approved clinical trials in lung cancer, Crohn's disease and ulcerative colitis.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally
Conference Objective
Meetings with potential Pharma partners and funders
Partnering Objective
Continue ongoing dialogue with respect to licensing of lead product indication, QBECO in inflammatory bowel disease
Delegate Contacts
Dr. Hal Gunn, founder and CEO of Qu Biologics, is a physician-entrepreneur who has dedicated his professional life to understanding how to optimally support the body’s immune response to chronic disease. Dr. Gunn is recognized both nationally and internationally as a leader in the field of supportive cancer care. Dr. Gunn obtained his Doctorate of Medicine and is a Clinical Assistant Professor at UBC’s School of Medicine. Dr. Gunn co-founded and lead InspireHealth, Canada’s leading supportive oncology centres, which supports the health, healing and immune system function of people undergoing cancer treatment and their families. Under Dr. Gunn’s leadership, InspireHealth grew to become a world leader in supportive cancer care. Dr. Gunn founded Qu Biologics in 2007.